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Brazil’s growing participation in the international 
clinical research scenario has been described in different 
publications1-4. Such growth brings professionalization in 
the sector and recognition of the country as a partner 
in international multicentric research. The multinational 
pharmaceutical industry, which previously concentrated 
its efforts to include patients in protocols in the United 
States and in Europe, has been expanding its horizons in 
search for capable research centers in Eastern Europe, Lat-
in America and Asia, thus amplifying its capacity to recruit 
patients5. 
An article published by Thiers et al. describes a glo-
balization trend in clinical studies, taking as a parameter 
the density of studies by country: 1) although clinical trials 
are still mostly performed in the traditional – developed 
– countries, nearly all these countries experienced a nega-
tive growth in their relative participation between 2002 
and 2006; 2) individually, emerging economies still show 
a relatively small participation; 3) in terms of quantity of 
research centers, emerging economies grow quicker than 
traditional countries; 4) a substantial and growing propor-
tion of studies have been conducted in these emerging re-
gions1.
At the same time, the so-called globalization of clini-
cal research offers training and qualification opportunities 
to research centers in these regions, by means of an inter-
change of information, a development and an improve-
ment of the teaching and research methods, as well as the 
provision of new therapeutic options to patients5. Multi-
centric studies, usually designed in conjunction with cen-
ters of excellence and regulating agencies, are elaborated 
by contemplating the latest developments about the dis-
ease researched, selecting treatments denominated “state 
of the art”, that is, those considered as the present day stan-
dard of treatment for a certain clinical condition. 
Until recently, drugs were evaluated by clinical trials 
only in countries located in the northern hemisphere, be-
ing approved for use based upon dossiers resulting only 
from studies performed in those countries. Thus, the 
Brazilian population used (and uses) drugs whose safety 
and efficacy have not been, mandatorily, evaluated in our 
country. It is not by chance that a study5 published in the 
New England Journal of Medicine, in 2009, highlights 
the concern of its authors with the growing inclusion of 
patients from other countries in clinical trials and, there-
fore, the lesser representativeness of the North-American 
population in researches. Would results from such trials be 
generalized to North-American patients? Would the exter-
nal validity of the studies still be ensured?
By following this trend of  clinical research’s growth 
in the world and, particularly, in Brazil, both the National 
Agency for Sanitary Surveillance (Agência Nacional de 
Vigilância Sanitária – ANVISA) and the National Com-
mission on Ethics in Research (Comissão Nacional de 
Ética em Pesquisa – CONEP) have been working towards 
widening the ethical debate on scientific investigation in 
health, through active participation in several meetings 
and forums, listening to partners in the academic and 
private sectors. The objective is to improve and accelerate 
the approval process of clinical trials in the country, while 
simultaneously maintaining the ethical and procedural 
strictness that this subject demands. 
It is also worth stressing, as a relatively recent advance 
in this area, the creation, in 2005, of the National Network 
of Clinical Research Units Linked to Teaching Hospitals 
(Rede Nacional de Unidades de Pesquisa Clínica ligadas 
a Hospitais de Ensino), by the Department of Science and 
Technology and Strategic Input of the Ministry of Health 
(Secretaria de Ciência e Tecnologia e Insumos Estratégi-
cos do Ministério da Saúde, SCTIE-MS), formed, at the 
time, by 14 centers in different localities in the Brazilian 
territory, which were selected by means of a public call and 
later amplified to 19 centers. More recently, this number 
grew to 30 centers6. The strategic interest of this action is 
to create clinical research centers with a specialized labor 
force and adequate technical-scientific training in good 
practices of clinical research; appropriate infrastructure 
to follow national and international research protocols, 
whether unicentric or multicentric; and serving the grow-
ing demand for participation of Brazilian centers in large 
clinical trials, as well as in national trials that are a priority 
in public health7,8.
This whole scenario takes place in an environment 
of economic stability, after decades of political instability 
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and ination in Brazil and Latin America. Several coun-
tries went through important economic changes over the 
last years. Democracy was established in most countries 
in this region. As a consequence, governments have been 
adopting policies focusing on scientific and technological 
development and on building solid foundations to support 
all these initiatives.3
It is important to say that the work performed in clini-
cal research also focuses on the patient, who many times 
does not have access to better treatment options available. 
By means of adequately designed research protocols they 
are provided with the most modern treatment or proce-
dures, besides state of the art health care, which is required 
by research protocols. 
Ethical conduct is the guiding line in all of these proj-
ects, and it is ensured by a previous approval of the re-
search protocols given by the Research Ethics Commit-
tees (REC) of the institutions where they are performed. 
In Brazil, the international multicentric study protocols 
are also submitted for the approval of CONEP and AN-
VISA, which evaluates sanitary aspects of the project and 
provides authorizations for the import of materials 
and drugs needed for the study. In the case of national 
trials, the ethical warranty granted by CONEP is usually 
not necessary. However, all clinical trials with products 
subject to sanitary registration, even if they do not require 
an import license (IL), must submit the process for AN-
VISA’s approval9.
New drugs and/or procedures should only be approved 
after the conduction of qualified randomized clinical tri-
als which have an adequate statistical power. These are the 
present definitions of evidence-based medicine, which 
proclaim the randomized clinical trials or the systematic 
reviews10 a degree of recommendation A (evidence level I). 
Brazil, a country that has been gaining prominence 
among emerging nations, fortunately can no longer be 
compared to countries where there is no universal access 
to health. Here, this right is granted by the Federal Con-
stitution of 1988, Article 19611. Another point in which 
Brazil stands out from the others in terms of development 
is the historic tradition of the ethical defense of research 
participants, by means of strong and fully enforced ethical 
resolutions.
RESEARCH IN DEVELOPING COUNTRIES 
Recently, much has been said about research in developing 
countries, where globalization has provided the arrival of 
more research and investment for the country in a general 
way. In this case, it becomes important to describe exactly 
what is understood by a developing country.  
There is no consensus among the various schools of 
economic thought about the definition of a country’s de-
velopment. The most common one is the classification 
based on the per capita GDP (Gross Domestic Product), 
as used by the International Monetary Fund (IMF) or the 
World Bank. Brazil holds the 63rd position in the IMF 
classification and the 54th position in the World Bank 
ranking, being classified as an emerging and develop-
ing economy (base year 2008)12. However, this criteria is 
much criticized, since a country like Qatar, for example, 
has one of the highest per capita incomes in the world 
(US$ 93,204.00 yearly), but is not included in any usual list 
of developed countries.
The United Nations (UN) developed an index  which 
goes beyond mere economic criteria and has made stan-
dards to the evaluation of the well being of a certain popu-
lation, the Human Development Index (HDI), which com-
prises three dimensions: wealth, education and average 
life expectancy. Developed countries usually have a high 
or very high HDI. According to this criterion, Brazil has 
a HDI of 0.699 (high). Table 1 shows the per capita GDP 
(2008) and HDI (2010) of the main emerging countries 
(BRICS: Brazil, Russia, India, China and, more recently, 
South Africa) and of some developed countries for com-
parison13,14.
Such considerations are important, since Brazil fortu-
nately must no longer be compared to other developing 
countries, since it presently holds a distinctive position in 
the world scenario, very different from the one it had some 
years ago. In the clinical research field, one can proudly 
make the same statement. It is not possible to compare 
Brazil with countries like India, where there is not even a 
medical ethics code15.
Characteristics of exploitation of research subjects are 
sometimes mentioned, such as: 1) participation of these 
countries just to avoid a more rigorous ethical supervision 
existing in the countries where the research projects are 
designed; 2) use of research subjects who are economically 
disadvantaged in order to accelerate recruitment and, even-
tually, submit them to procedures that are not recommend-
ed and that would not be approved in developed countries; 
 
Per capita GDP (IMF)
(US$)
HDI
United States 47440 0.9
Germany 44729 0.8
United Kingdom 43734 0.8
Spain 35117 0.8
Russia 8736 0.719
Brazil 8114 0.699
China 3769 0.663
South Africa 5707 0.597
India 1075 0.519
Table 1 – Comparative per capita GDP and HDI among the 
BRICS countries and some developed countries (organized 
by decreasing order of HDI)
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3) non-availability of the benefits produced by the end of 
the study to the research participants, or even to the com-
munities that welcomed the research16. Exploitation could 
be defined as the act of taking unfair advantage of others 
in order to serve ones own interests17. In this sense, testing 
new interventions in populations who will not have access 
to the results and benefits after the research is considered 
an act of exploitation, since one population (from develop-
ing countries, which take part in clinical researches) is be-
ing taken advantage of to serve another population (from 
developed countries, where the new drug will be sold).
In developed countries where, in the past, research was 
predominantly performed, the subjects who participated 
in it are later rewarded with direct benefits by means of 
availability of new products and services. Indirectly, they 
(and the whole population of those countries) are also 
benefited by the creation of jobs and wealth brought by 
the industry17.
The vulnerability of patients in developing countries 
represents a great concern and demands special attention 
from the people involved in ethical and regulatory analy-
sis, in the sense that they represent the adequate and nec-
essary mechanisms to protect vulnerable patients3. Popu-
lations of patients that, for some reason, are not considered 
in full possession of autonomy are named “vulnerable 
populations”. Lack of autonomy can lead to a subordina-
tion relationship, like that which occurs with prisoners, for 
example18. Resolution 196/96 defines vulnerability as the 
state of people or groups that, for any reason, have their 
ability for self-determination diminished, mainly regard-
ing  informed consent16.
In public health, it is observed that researches and poli-
cies designed to protect the most vulnerable eventually 
protects all the members of society19. Therefore, a concern 
for vulnerable populations that can be included in clini-
cal researches is totally understandable and healthy. Ide-
ally, developing countries would create their own systems 
for ethical review of research, with coherent documents in 
relation to local contexts, but evidently based on interna-
tionally accepted codes.
Denunciations of ethical deviations, like attempts to 
“relax protection norms” from the Declaration of Hel-
sinki20 and the issue of the “double  standard”21-23 are 
mentioned many times. The double standard refers to the 
existence of differentiated ethical standards for research 
protocols, theoretically justified due to the socioeconomic 
diversity of the different countries. In the case of popula-
tions for which more modern treatments are not available, 
some believe that it is acceptable to use different therapeu-
tic options from the ones considered to be the gold stan-
dard (or even placebo), since at least a chance of treatment 
would be offered to patients, in case they were drawn for 
the experimental treatment group. Justifications for the 
“double-standard” are, however, questionable, since the 
lack of access to drugs does not characterize a natural in-
equality, but a situation of social exclusion. The existing 
difficulties in such cases are many times more related to 
the poor capacity of drug distribution. Access to health 
care is not entirely determined by individual choices, but 
also by health policies of the country, by its commitment 
to the health of the population and resource distribution24.
An article published in 2009 by Garrafa and Lorenzo23 
comments on the last revision of the Declaration of Hel-
sinki. According to the authors, the change introduced 
in the Declaration, for example, in the topic referring 
to care after the study, “legitimates secondary and indi-
rect benefits and consolidates the option for sponsors to 
make deals which mean lower costs for their companies. 
Such deals [...] involving subjects and social groups with a 
low level of education and in social exclusion conditions, 
all this evaluated by committees which possibly pres-
ent the problems previously described23”. Certainly this 
does not reect the reality any longer, because Brazil has 
evolved with the opportunities to take part in research 
and training, and so did its ethical and sanitary legisla-
tion. Thus, the country has its own systems of ethical re-
view of research, which are autonomous and sufficiently 
developed and adequate to the local contexts (Resolutions 
CNS 196/1996, 251/1997, 292/1999, 301/2000, 404/2008 
and RDC 39/2008, just to name the most relevant ones). 
Additionally, they are subjected to mechanisms of social 
control, which many times cause  protocols that were 
originally approved in developed countries to be rejected 
in this country.
The number of ongoing projects in developed coun-
tries that are disapproved by CONEP and unauthorized in 
Brazilian territory is not small. This independence is surely 
welcome, provided it is considered in an appropriate way 
and does not hinder the access of Brazilian patients to 
research protocols whose additional therapeutic options 
may save their lives. Without any doubt, it is unethical to 
approve research projects that might harm patients, but it 
is equally unethical not to approve projects that can ben-
efit them. In fact, there is no evidence that ethics com-
mittees approve researches that present excessive risk, but 
evidence suggests that committees are extremely cautious, 
sometimes prohibiting researches presenting a favorable 
risk-benefit relationship25.
Additionally, diversity is considered important for 
the generalization of research results (external validity). 
Thus, “race” refers to how people’s genetics is evidenced 
in physical characteristics such as skin color, facial as-
pects, metabolic paths, among others. “Ethnicity” refers 
to race plus place of birth, religion, diet, cultural aspects, 
among other factors. Both race and ethnicity can affect 
a patient’s response to drugs. Besides, ethnicity affects 
the attitude and probability of patients to be included in 
clinical trials. The importance of including patients from 
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several countries becomes evident, representing the di-
versity of the existing populations26.
In an article that discusses ethics when including pa-
tients from developing countries in clinical researches 
in oncology, Mano et al.27 emphasize that, although the 
individual benefit for the patient must be taken into ac-
count, the real benefit to society might, many times, be 
minimal. According to the authors, it is also possible that 
only patients from healthier economies will benefit from 
data generated by the studies. In an era of new biologic 
therapies, the issue of access to high cost treatments must 
become one of the biggest challenges to society and, in 
fact, it can extrapolate from the science field, involving 
society as a whole. It would be unacceptable to make a 
whole effort for the development of new drugs and tech-
nologies that would be available only for a small group of 
patients. Prospective agreements must be signed, so as to 
ensure that the researches benefit the population of the 
countries where they are conducted. Ultimately, authors 
stress that it is not about discouraging research in devel-
oping countries; rather, it is about defining agreements 
among the several parties, in such a way that research 
can still be carried on in these countries, while prevent-
ing them from becoming mere assembly lines27.
Some authors consider that, in clinical trials sponsored 
by industries, most researches do not reect the character-
istics and the epidemiology of developing countries, and 
that they limit “in a perverse way”, the possibility national 
researchers have to make significant alterations in the proj-
ect28. Thus, they suggest that the investigator (researcher) 
should not be called as such, since he/she simply applies 
the protocol, without having participated in its design or 
having made any criticism or intellectual addition to the 
project. In this case, the research leader would be best des-
ignated as the “research executor” or “service provider”, 
and not a researcher per se. This scenario has been chang-
ing over the last years, with a more active participation of 
native researchers, thanks to their good university educa-
tion and specialization, in addition to the growing partici-
pation Brazil has in international multicentric studies and 
the consequent training and qualification of researchers in 
research methodologies.
THE ROLE OF CLINICAL RESEARCH IN THE COUNTRY´S 
DEVELOPMENT 
Around two billion people in the world lack essential 
drugs. The state is the main responsible party for pro-
viding these drugs. However, other actors, such as the 
pharmaceutical industry, also share this responsibility 
through the development and further commercialization 
of drugs.  They contribute, in their own way, to numer-
ous advancements in improving the quality of life of peo-
ple, and helping to save lives. But this contribution also 
brings responsibilities29. 
Globalization brought clinical research, previously only 
performed in the United States and in Europe, to Latin 
America, as well as to Eastern Europe. As the structure 
and the organization of clinical research demand the use of 
standardized international procedures and good practices, 
these activities induce the development of management 
competencies and technological qualifications that can be 
shared with other areas of industries and research institu-
tions4. As commented by Marandola et al.4, “Brazil needs 
to consider clinical research as a strategic area if it wants to 
receive growing international investments, take advantage 
of biomedical advancements for the population and  foster a 
technological development in the sector”.
Quental30, on her turn, comments, in a publication 
from 2006: “in order to strengthen this sector, for the ben-
efit of national interests, it is necessary to minimize ob-
stacles so that all the elements of the system are strong and 
their interactions are virtuous. In this sense, some qualifi-
cations must be developed”. Part of the present difficulty in 
this field seems to happen due to the scarcity of qualified 
human resources, and some actions are needed to support 
the constitution and strengthening of research groups, 
and related service companies. The retention of human 
resources is another point to be studied and improved30.
Translational medicine, emerging as a new discipline, 
brings along the concept of translation of the basic research 
knowledge to clinical research and, going further, of the evi-
dences generated by clinical research to concrete proposals 
of a sustainable solution to public health problems31,32.
There are data in the literature that point out the fact 
that clinical research can even improve the medical care 
of the institution as a whole. The existence of an adequate 
infrastructure, qualified and specialized professionals, and 
adherence to good clinical practices constitute required 
factors which are fundamental to the participation of hos-
pitals in clinical trials. Observing these factors can benefit 
the institution involved and its patients. Articles recently 
published show that participation in clinical trials is close-
ly associated to a better evaluation, treatment and follow-
up of the patients in a hospital environment33,34. However, 
data are still insufficient and controversial. A systematic 
review performed by the Cochrane Foundation, in 2008, 
could not demonstrate a positive effect of the performance 
of clinical research in health care35. 
Schaefer36, in a controversial 2009 article, addresses 
the obligation to participate in biomedical research, and 
defends that biomedical knowledge is a public good. 
Therefore, participating in clinical research is a way to 
support a public good, thus, every individual must par-
ticipate. According to the author, a public good holds two 
characteristics: 1) the individual use of such good does 
not diminish its use by others, and 2) it is not possible 
to prevent individuals from using this asset. On the oth-
er hand, a good is private when its use by an individual 
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diminishes its use by others and/or, when it is given to one 
individual, this prevents its use by others. According to 
his reasoning, individuals take part in a clinical research 
when they have a good reason to do it, whereas the op-
posite should happen, that is, they should always partici-
pate, unless they had a good reason not to do it! In addi-
tion to this, the obligation to participate in research does 
not eliminate the right of an individual to withdraw his/
her authorization, if and when he/she deems fit36. A criti-
cal reading of this article allows for the identification of a 
aw in its premise, since it does not distinguish between 
research done on important clinical or scientific issues, 
which, in fact, add substantial value to society, as opposed 
to research done to answer regulatory, and not clinical, is-
sues. The first kind of research could be considered an ob-
ligation, according to a concept of public good by Schaefer, 
but not the second type37.
CONCLUSION
It has been said that Brazil is no longer the country of the 
future, rather the country of the present. Maybe a still op-
timistic, but slightly more conservative term should be: 
“a country with a future”. And, for that matter, it is nec-
essary to think of the goals to be accomplished over the 
next years, in order to build a solid, strong environment, 
which is adequate to the moment and the opportunities 
our country has been experiencing. It is necessary to care 
for human resources, our real talents, in a responsible and 
planned way, by giving them incentives to continue invest-
ing in our country and in our future. With the inclusion 
of Brazil in the so-called “emerging countries”, we have an 
opportunity, not to be missed, to reinforce this virtuous 
cycle already initiated and to transform the country and 
its professionals from coadjutants into protagonists. This 
is also true for the economy, education, health and, within 
it, clinical research. And it is worth remembering: with op-
portunity comes responsibility. Losing an opportunity is 
worse than not having it.
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